NBY insider filing: Framework stakes in Series D/E preferred
Rhea-AI Filing Summary
NovaBay Pharmaceuticals (NBY): Initial insider ownership filed. Framework Ventures IV L.P. and affiliated entities jointly filed a Form 3 disclosing preferred equity positions tied to NovaBay common stock.
On October 9, 2025, Framework LP purchased 220,663 shares of Series D Non-Voting Convertible Preferred Stock, which is convertible into a maximum of 1,164,117 shares of common stock, and acquired rights and obligations to purchase 134,375 shares of Series E Non-Voting Convertible Preferred Stock.
Following stockholder approval of proposals 5 and 9 at the October 16, 2025 annual meeting, each share of Series D Preferred converts into 160 common shares at the holder’s option or within three business days of the meeting, and each share of Series E Preferred converts into 160 common shares at the holder’s option or within thirty business days. The filing indicates a Director relationship and was submitted jointly pursuant to a Joint Filing Agreement dated October 20, 2025.
Positive
- None.
Negative
- None.